Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma
- 15 July 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (2), 616-623
- https://doi.org/10.1182/blood-2007-01-066704
Abstract
Targeting cytotoxic drugs to cancer cells using antibody–drug conjugates (ADCs), particularly those with stable linkers between the drug and the antibody, could be an effective cancer treatment with low toxicity. However, for stable-linker ADCs to be effective, they must be internalized and degraded, limiting potential targets to surface antigens that are trafficked to lysosomes. CD79a and CD79b comprise the hetrodimeric signaling component of the B-cell receptor, and are attractive targets for the use of ADCs because they are B-cell–specific, expressed in non-Hodgkin lymphomas (NHL), and are trafficked to a lysosomal-like compartment as part of antigen presentation. We show here that the stable-linker ADCs anti-CD79b-MCC-DM1 and anti-CD79b-MC-MMAF are capable of target-dependent killing of nonHodgkin lymphoma cell lines in vitro. Further, these 2 ADCs are equally effective as low doses in xenograft models of follicular, mantle cell, and Burkitt lymphomas, even though several of these cell lines express relatively low levels of CD79b in vivo. In addition, we demonstrate that anti-CD79b ADCs were more effective than anti-CD79a ADCs and that, as hypothesized, anti-CD79b antibodies downregulated surface B-cell receptor and were trafficked to the lysosomal-like major histocompatibility complex class II–positive compartment MIIC. These results suggest that anti-CD79b-MCC-DM1 and anti-CD79b-MC-MMAF are promising therapeutics for the treatment of NHL.Keywords
This publication has 68 references indexed in Scilit:
- Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemiaInternational Immunology, 2006
- Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target AntigenCancer Research, 2006
- A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow CytometryImmunological Investigations, 2006
- Drug-conjugated monoclonal antibodies for the treatment of cancerCurrent Opinion in Pharmacology, 2005
- Arming antibodies for cancer therapyCurrent Opinion in Pharmacology, 2005
- Multimodality Therapies and Optimal Schedule of Antibodies: Rituximab in Lymphoma as an ExampleHematology-American Society Hematology Education Program, 2005
- Low-Grade LymphomaHematology-American Society Hematology Education Program, 2004
- Diffuse Aggressive LymphomaHematology-American Society Hematology Education Program, 2004
- Induction of Tyrosine Phosphorylation in Human B Lineage Cells by Crosslinking MB-1 Molecule of B Cell Receptor-Related Heterodimer ComplexBiochemical and Biophysical Research Communications, 1993
- Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane trafficCell, 1991